US Equities Analysis

IDXX — Idexx Laboratories

IDXX Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 43.93B.

1.2 Competition

The industry is highly competitive with low barriers to entry and significant rivalry among existing players. Beta of 1.54 reflects elevated volatility from competitive dynamics. Companies compete on pricing, innovation, and scale.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 31.78%
Profit Margins 24.63%
Return on Equity 72.91%
Return on Assets 26.46%
Free Float 0.08B
Short Int % Utilisation 3.16%

2.2 Growth

Metric Value
Revenue Growth 14.3%
Free Cash Flow 0.79B
EBITDA 29.0 (Ratio)
Enterprise Value 44.84B
EV/Revenue 10.09
EV/EBITDA 29.0

Revenue growth of 14.3% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) 5.12%
Risk / Std Dev (Ann.) 35.34%
Sharpe Ratio (rf=4.5%) 0.02
Beta 1.54

2.5 Valuation

Metric Value
P/E (Forward) 33.72
Price/Book 27.56
EV/Revenue 10.09
EV/EBITDA 29.0
Enterprise Value / NOPAT 35.71
FCF Yield (%) 1.84%
Price / Earnings 39.83
Price / Book 27.56
Enterprise Value / EBITDA 28.21

Forward P/E of 34x is at a moderate premium, reflecting growth expectations.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of 5.1% with annualised volatility of 35.3%, yielding a Sharpe ratio of 0.02 (rf=4.5%). The risk-adjusted return is positive but modest on a historical basis. With a beta of 1.5, the stock is significantly more volatile than the market — it amplifies both upside and downside moves.


us-equitystockequityidxxhealth-carehealth-care-equipmentnasdaq